权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Kinase Inhibition in Kidney Cancer

肾癌中的激酶抑制

基本信息

批准号：
9752261
负责人：
WILLIAM Y. KIM
金额：
$ 41.95万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-09-02 至 2021-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9752261
关键词：
Cell Line Cells Characteristics Chemicals Clear Cell Clear cell renal cell carcinoma Clinical Combined Modality Therapy Cytotoxic Chemotherapy Dasatinib Endothelial Growth Factors Receptor Expression Profiling FDA approved FRAP1 gene Family Genetic Transcription Genome Genomics Heterogeneity Histologic Human In Vitro Incidence Janus kinase Mass Spectrum Analysis Molecular Biology Mutation Pathway interactions Patients Phosphotransferases Play Protein Tyrosine Kinase Proteomics RNA Renal Cell Carcinoma Renal carcinoma Resistance Role Running SDZ RAD Signal Transduction Signal Transduction Pathway TYK2 Testing Therapeutic Time United States Validation Vascular Endothelial Growth Factors Vegf Inhibitor Work Xenograft Model Xenograft procedure base combinatorial high throughput screening in vivo inhibitor/antagonist innovative technologies member novel predictive marker response response biomarker src-Family Kinases targeted treatment therapeutic evaluation therapy development tumor tumor xenograft

项目摘要

ABSTRACT The incidence of renal cell carcinoma (RCC) is on the rise. 65,000 new cases occur annually in the United States. Vascular endothelial growth factor receptor (VEGFR) and mammalian target of rapamycin (mTOR) inhibitors are FDA approved and commonly used treatments for advanced RCC but result in increases in overall survival by only months. At this time, the most druggable portion of the genome remains the kinome. Through unbiased, high-throughput screening we have identified and validated the therapeutic value of a novel kinase in RCC, tyrosine kinase 2 (TYK2: a member of the Janus Kinase family) and demonstrate that it plays a role in mTOR inhibitor resistance. We have characterized a signaling network in which TYK2 positively regulates the SRC family kinases (SFKs) and demonstrate that dual inhibition of mTOR and SRC with everolimus and dasatinib induces tumor regression in vivo. Based on these results we hypothesize that inhibition of the TYK2/SRC axis is a tractable therapeutic strategy in a subset of RCC, that we can define predictive markers of TYK2/SRC inhibitor response, and that defining the kinomic landscape of RCC and its response to mTOR inhibition will lead to further combinatorial targets.

抽象的肾细胞癌（RCC）的发病率呈上升趋势。美国每年出现 65,000 例新病例国家。血管内皮生长因子受体 (VEGFR) 和哺乳动物雷帕霉素靶点 (mTOR) 抑制剂是 FDA 批准的、常用的晚期肾细胞癌治疗方法，但会导致总生存期仅延长几个月。此时，基因组中最容易药物化的部分仍然是激酶组。通过公正的高通量筛选，我们已经确定并验证了一种新型药物的治疗价值 RCC 中的激酶，酪氨酸激酶 2（TYK2：Janus 激酶家族的成员）并证明它发挥着 mTOR 抑制剂耐药性中的作用。我们已经表征了一个信号网络，其中 TYK2 积极调节 SRC 家族激酶 (SFK) 并证明 mTOR 和 SRC 的双重抑制依维莫司和达沙替尼在体内诱导肿瘤消退。根据这些结果我们假设 TYK2/SRC 轴的抑制是 RCC 子集中的一种易于处理的治疗策略，我们可以将其定义为 TYK2/SRC 抑制剂反应的预测标记，以及定义 RCC 及其运动组学景观的标记对 mTOR 抑制的反应将导致进一步的组合目标。